Skip to main content
Top
Published in: Health Economics Review 1/2014

Open Access 01-12-2014 | Research

Economic impact of HIV/AIDS: a systematic review in five European countries

Authors: Marta Trapero-Bertran, Juan Oliva-Moreno

Published in: Health Economics Review | Issue 1/2014

Login to get access

Abstract

The HIV/AIDS disease represent a priority for all health authorities in all countries and it also represents serious added socioeconomic problems for societies over the world. The aim of this paper is to analize the economic impact associated to the HIV/AIDS in an European context. We conducted a systematic literature review for five different countries (France, Germany, Italy, Spain and United Kingdom) and searched five databases. Three types of analyses were undertaken: descriptive statistics; quantitative analysis to calculate mean costs; and comparison across countries. 26 papers were included in this study containing seventy-six cost estimates. Most of the studies analyzed the health care cost of treatment of HIV/AIDS. Only 50% of the cost estimates provided mean lymphocyte count describing the patients’ disease stage. Approximately thirty percent of cost estimates did not indicate the developmental stage of the illness in the patients included. There is a high degree of variability in the estimated annual cost per patient of the treatments across countries. There is also a great disparity in total healh care costs for patients with lymphocyte counts between 200CD4+/mm3 and 500 CD4/mm3, although the reason of variation is unclear. In spite of the potential economic impact in terms of productivity losses and cost of formal and informal care, few studies have set out to estimate the non-medical costs of HIV/AIDS in the countries selected. Another important result is that, despite the low HIV/AIDS prevalence, its economic burden is very relevant in terms of the total health care costs in this five countries. This study also shows that there are relatively few studies of HIV costs in European countries compared to other diseases. Finally, we conclude that the methodology used in many of the studies carried out leaves ample room for improvement and that there is a need for these studies to reflect the economic impact of HIV/AIDS beyond health care including other components of social burden.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fauci AS: The AIDS Epidemic. Considerations for the 21st Century. N Engl J Med 1999, 341: 1046–1050. 10.1056/NEJM199909303411406CrossRefPubMed Fauci AS: The AIDS Epidemic. Considerations for the 21st Century. N Engl J Med 1999, 341: 1046–1050. 10.1056/NEJM199909303411406CrossRefPubMed
2.
go back to reference Ojo K, Delaney M: Economic and demographic consequences of AIDS in Namibia: rapid assessment of the costs. Int J Health Plann Manage 1997, 12(4):315–326. 10.1002/(SICI)1099-1751(199710/12)12:4<315::AID-HPM492>3.0.CO;2-ACrossRefPubMed Ojo K, Delaney M: Economic and demographic consequences of AIDS in Namibia: rapid assessment of the costs. Int J Health Plann Manage 1997, 12(4):315–326. 10.1002/(SICI)1099-1751(199710/12)12:4<315::AID-HPM492>3.0.CO;2-ACrossRefPubMed
3.
go back to reference Beck EJ, Miners AH, Tolley K: The cost of HIV treatment and care. A global review. Pharmacoeconomics 2001, 19(1):13–39. 10.2165/00019053-200119010-00002CrossRefPubMed Beck EJ, Miners AH, Tolley K: The cost of HIV treatment and care. A global review. Pharmacoeconomics 2001, 19(1):13–39. 10.2165/00019053-200119010-00002CrossRefPubMed
5.
go back to reference Hellinger FJ: Economic Models of Antirretroviral Therapy: Searching for the Optimal Strategy. Pharmacoeconomics 2006, 24(7):631–42. 10.2165/00019053-200624070-00002CrossRefPubMed Hellinger FJ: Economic Models of Antirretroviral Therapy: Searching for the Optimal Strategy. Pharmacoeconomics 2006, 24(7):631–42. 10.2165/00019053-200624070-00002CrossRefPubMed
6.
go back to reference Oliva J: Labour participation of Spanish people living with HIV between 2001–2004. Health Econ 2010, 19: 491–500. 10.1002/hec.1487CrossRefPubMed Oliva J: Labour participation of Spanish people living with HIV between 2001–2004. Health Econ 2010, 19: 491–500. 10.1002/hec.1487CrossRefPubMed
7.
go back to reference Mooser V, Carr A: Antirretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol 2001, 12(3):313–9. 10.1097/00041433-200106000-00011CrossRefPubMed Mooser V, Carr A: Antirretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol 2001, 12(3):313–9. 10.1097/00041433-200106000-00011CrossRefPubMed
8.
go back to reference Mallon PW, Cooper DA, Carr A: HIV-associated lipodystrophy. HIV Med 2001, 2(3):166–73. 10.1046/j.1468-1293.2001.00071.xCrossRefPubMed Mallon PW, Cooper DA, Carr A: HIV-associated lipodystrophy. HIV Med 2001, 2(3):166–73. 10.1046/j.1468-1293.2001.00071.xCrossRefPubMed
9.
go back to reference Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España Med Clin (Barc) 2002, 119(19):721–724. 10.1016/S0025-7753(02)73556-2 Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España Med Clin (Barc) 2002, 119(19):721–724. 10.1016/S0025-7753(02)73556-2
10.
go back to reference Carr A, Cooper DA: Adverse effects of antirretroviral therapy. Lancet 2000, 356(9239):1423–30. 10.1016/S0140-6736(00)02854-3CrossRefPubMed Carr A, Cooper DA: Adverse effects of antirretroviral therapy. Lancet 2000, 356(9239):1423–30. 10.1016/S0140-6736(00)02854-3CrossRefPubMed
11.
go back to reference Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, Concia E: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338(5):286–90. 10.1056/NEJM199801293380503CrossRefPubMed Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, Concia E: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338(5):286–90. 10.1056/NEJM199801293380503CrossRefPubMed
12.
go back to reference Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD: Mortality in the Highly Active Antirretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study. J Acquir Immune Defic Synd 2006, 43(1):27–34. 10.1097/01.qai.0000233310.90484.16CrossRef Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD: Mortality in the Highly Active Antirretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study. J Acquir Immune Defic Synd 2006, 43(1):27–34. 10.1097/01.qai.0000233310.90484.16CrossRef
13.
go back to reference Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K: Increasing burden of liver disease in patients with HIV infection. Lancet 2011, 377(9772):1198–209. 10.1016/S0140-6736(10)62001-6CrossRefPubMed Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K: Increasing burden of liver disease in patients with HIV infection. Lancet 2011, 377(9772):1198–209. 10.1016/S0140-6736(10)62001-6CrossRefPubMed
14.
go back to reference Blas-Garcia A, Esplugues JV, Apostolova N: Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity. Curr Med Chem 2011, [Epub ahead of print]. Blas-Garcia A, Esplugues JV, Apostolova N: Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity. Curr Med Chem 2011, [Epub ahead of print].
16.
go back to reference Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN: Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006, 166(5):521–8. 10.1001/archinte.166.5.521CrossRefPubMed Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN: Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006, 166(5):521–8. 10.1001/archinte.166.5.521CrossRefPubMed
17.
go back to reference Achhra AC, Phanuphak P, Amin J: Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries. Curr Opin HIV AIDS 2011, [Epub ahead of print] Achhra AC, Phanuphak P, Amin J: Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries. Curr Opin HIV AIDS 2011, [Epub ahead of print]
18.
go back to reference Ledergerber B, Cavassini M, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Furrer H, Rickenbach M, Weber R: Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med 2011, 12(5):279–288. 10.1111/j.1468–1293.2010.00880.x. Epub 2010 Oct 18 10.1111/j.1468-1293.2010.00880.xCrossRefPubMed Ledergerber B, Cavassini M, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Furrer H, Rickenbach M, Weber R: Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med 2011, 12(5):279–288. 10.1111/j.1468–1293.2010.00880.x. Epub 2010 Oct 18 10.1111/j.1468-1293.2010.00880.xCrossRefPubMed
19.
go back to reference Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C: Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis 2010, 51(8):947–56. 10.1086/656415PubMedCentralCrossRefPubMed Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C: Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis 2010, 51(8):947–56. 10.1086/656415PubMedCentralCrossRefPubMed
20.
go back to reference HIV/AIDS surveillance in Europe 2008. European Centre for Disease Prevention and Control, Stockholm; 2009. HIV/AIDS surveillance in Europe 2008. European Centre for Disease Prevention and Control, Stockholm; 2009.
21.
go back to reference Kahn JG, Marseille E: Fighting global AIDS: the value of cost-effectiveness analysis. AIDS 2000, 14(16):2609–10. 10.1097/00002030-200011100-00026CrossRefPubMed Kahn JG, Marseille E: Fighting global AIDS: the value of cost-effectiveness analysis. AIDS 2000, 14(16):2609–10. 10.1097/00002030-200011100-00026CrossRefPubMed
22.
go back to reference Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piche A, Hankins CA: The Cost-effectiveness of Highly Active Antirretroviral Therapy., Canada 1991–2001. AIDS 2004, 18(18):2411–8.PubMed Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piche A, Hankins CA: The Cost-effectiveness of Highly Active Antirretroviral Therapy., Canada 1991–2001. AIDS 2004, 18(18):2411–8.PubMed
23.
go back to reference Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA: The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States. Med Care 2006, 44(11):990–7. 10.1097/01.mlr.0000228021.89490.2aCrossRefPubMed Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA: The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States. Med Care 2006, 44(11):990–7. 10.1097/01.mlr.0000228021.89490.2aCrossRefPubMed
24.
go back to reference King JT Jr, Justice AC, Roberts MS, Chang CC, Fusco JS: Long-term HIV/AIDS Survival Estimation in the Highly Active Antirretroviral Therapy Era. Med Decis Making 2003, 23(1):9–20. 10.1177/0272989X02239652CrossRefPubMed King JT Jr, Justice AC, Roberts MS, Chang CC, Fusco JS: Long-term HIV/AIDS Survival Estimation in the Highly Active Antirretroviral Therapy Era. Med Decis Making 2003, 23(1):9–20. 10.1177/0272989X02239652CrossRefPubMed
25.
go back to reference Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D: Long-term Impact of Highly Active Antirretroviral Therapy on HIV-related Health Care. J Acquir Immune Defic Syndr 2001, 27(1):14–9. 10.1097/00126334-200105010-00003CrossRefPubMed Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D: Long-term Impact of Highly Active Antirretroviral Therapy on HIV-related Health Care. J Acquir Immune Defic Syndr 2001, 27(1):14–9. 10.1097/00126334-200105010-00003CrossRefPubMed
26.
go back to reference Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, Harrigan BP, Sobolev B, Montaner JS: The Direct Costs of HIV/AIDS Care. Lancet Infect Dis 2006, 6(3):171–7. 10.1016/S1473-3099(06)70413-3CrossRefPubMed Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, Harrigan BP, Sobolev B, Montaner JS: The Direct Costs of HIV/AIDS Care. Lancet Infect Dis 2006, 6(3):171–7. 10.1016/S1473-3099(06)70413-3CrossRefPubMed
27.
go back to reference Scitovsky AA, Rice DP: Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987, 102(1):5–17.PubMedCentralPubMed Scitovsky AA, Rice DP: Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987, 102(1):5–17.PubMedCentralPubMed
28.
go back to reference Yelin EH, Greenblatt RM, Hollander H, McMaster JR: The impact of HIV-related illness on employment. Am J Public Health 1991, 81(1):79–84. 10.2105/AJPH.81.1.79PubMedCentralCrossRefPubMed Yelin EH, Greenblatt RM, Hollander H, McMaster JR: The impact of HIV-related illness on employment. Am J Public Health 1991, 81(1):79–84. 10.2105/AJPH.81.1.79PubMedCentralCrossRefPubMed
29.
go back to reference Leigh JP, Lubeck DP, Farnham P, Fries JF: Potential and actual workdays lost among patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8(4):392–8. 10.1097/00042560-199504000-00011PubMed Leigh JP, Lubeck DP, Farnham P, Fries JF: Potential and actual workdays lost among patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8(4):392–8. 10.1097/00042560-199504000-00011PubMed
30.
go back to reference Laursen E, Larsen L: Socio-economic status of AIDS patients. Scand J Soc Med 1995, 23(3):189–92.PubMed Laursen E, Larsen L: Socio-economic status of AIDS patients. Scand J Soc Med 1995, 23(3):189–92.PubMed
31.
go back to reference Dray-Spira R, Lert F, Marimoutou C, Bouhnik AD, Obadia Y: Socio-economic conditions, health status and employment among persons living with HIV/AIDS in France in 2001. AIDS Care 2003, 15(6):739–48. 10.1080/09540120310001618595CrossRefPubMed Dray-Spira R, Lert F, Marimoutou C, Bouhnik AD, Obadia Y: Socio-economic conditions, health status and employment among persons living with HIV/AIDS in France in 2001. AIDS Care 2003, 15(6):739–48. 10.1080/09540120310001618595CrossRefPubMed
32.
go back to reference Rabkin JG, McElhiney M, Ferrando SJ, Van Gorp W, Lin SH: Predictors of employment of men with HIV/AIDS: a longitudinal study. Psychosom Med 2004, 66(1):72–8. 10.1097/01.PSY.0000108083.43147.6DCrossRefPubMed Rabkin JG, McElhiney M, Ferrando SJ, Van Gorp W, Lin SH: Predictors of employment of men with HIV/AIDS: a longitudinal study. Psychosom Med 2004, 66(1):72–8. 10.1097/01.PSY.0000108083.43147.6DCrossRefPubMed
33.
go back to reference Goldman DP, Bao Y: Effective HIV treatment and the employment of HIV(+) adults. Health Serv Res 2004, 39(6 Pt 1):1691–712. 10.1111/j.1475-6773.2004.00313.xPubMedCentralCrossRefPubMed Goldman DP, Bao Y: Effective HIV treatment and the employment of HIV(+) adults. Health Serv Res 2004, 39(6 Pt 1):1691–712. 10.1111/j.1475-6773.2004.00313.xPubMedCentralCrossRefPubMed
34.
go back to reference Bernell SL, Shinogle JA: The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook. Health Policy 2005, 71(2):255–64. 10.1016/j.healthpol.2004.08.012CrossRefPubMed Bernell SL, Shinogle JA: The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook. Health Policy 2005, 71(2):255–64. 10.1016/j.healthpol.2004.08.012CrossRefPubMed
35.
go back to reference Sendi P, Brouwer WB, Bucher HC, Weber R, Battegay M: When time is more than money: The allocation of time between work and leisure in HIV-infected patients. Soc Sci Med 2007, 64(11):2355–61. 10.1016/j.socscimed.2007.02.032CrossRefPubMed Sendi P, Brouwer WB, Bucher HC, Weber R, Battegay M: When time is more than money: The allocation of time between work and leisure in HIV-infected patients. Soc Sci Med 2007, 64(11):2355–61. 10.1016/j.socscimed.2007.02.032CrossRefPubMed
38.
go back to reference Liu GG, Guo JJ, Smith SR: Economic costs to business of the HIV/AIDS epidemic. Pharmacoeconomics 2004, 22(18):1181–1194. 10.2165/00019053-200422180-00003CrossRefPubMed Liu GG, Guo JJ, Smith SR: Economic costs to business of the HIV/AIDS epidemic. Pharmacoeconomics 2004, 22(18):1181–1194. 10.2165/00019053-200422180-00003CrossRefPubMed
39.
go back to reference Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P: The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain. BMC Health Serv Res 2009, 9: 55–63. 10.1186/1472-6963-9-55PubMedCentralCrossRefPubMed Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P: The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain. BMC Health Serv Res 2009, 9: 55–63. 10.1186/1472-6963-9-55PubMedCentralCrossRefPubMed
Metadata
Title
Economic impact of HIV/AIDS: a systematic review in five European countries
Authors
Marta Trapero-Bertran
Juan Oliva-Moreno
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Health Economics Review / Issue 1/2014
Electronic ISSN: 2191-1991
DOI
https://doi.org/10.1186/s13561-014-0015-5

Other articles of this Issue 1/2014

Health Economics Review 1/2014 Go to the issue